Association/NN
of/IN
HLA/NN
Genotype/NN
and/CC
Fulminant/JJ
Type/NN
1/CD
Diabetes/NNS
in/IN
Koreans/NNS
./.
====================
Fulminant/JJ
type/NN
1/CD
diabetes/VBZ
(/(
T1DM/NN
)/)
is/VBZ
a/DT
distinct/JJ
subtype/NN
of/IN
T1DM/NN
that/DT
is/VBZ
characterized/VBN
by/IN
rapid/JJ
onset/NN
hyperglycemia/NN
,/,
ketoacidosis/NN
,/,
absolute/JJ
insulin/NN
deficiency/NN
,/,
and/CC
near/JJ
normal/JJ
levels/NNS
of/IN
glycated/JJ
hemoglobin/NN
at/IN
initial/JJ
presentation/NN
./.
====================
Although/IN
it/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
class/NN
II/CD
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
genotype/NN
is/VBZ
associated/VBN
with/IN
fulminant/JJ
T1DM/NN
,/,
the/DT
genetic/JJ
predisposition/NN
is/VBZ
not/RB
fully/RB
understood/VBN
./.
====================
In/IN
this/DT
study/NN
we/PRP
investigated/VBD
the/DT
HLA/NN
genotype/NN
and/CC
haplotype/JJ
in/IN
11/CD
Korean/JJ
cases/NNS
of/IN
fulminant/JJ
T1DM/NN
using/VBG
imputation/NN
of/IN
whole/JJ
exome/JJ
sequencing/NN
data/NNS
and/CC
compared/VBD
its/PRP$
frequencies/NNS
with/IN
413/CD
participants/NNS
of/IN
the/DT
Korean/JJ
Reference/NN
Panel/NN
./.
====================
The/DT
HLA-DRB1*04:05–HLA-DQB1*04:01/NN
haplotype/JJ
was/VBD
significantly/RB
associated/VBN
with/IN
increased/VBN
risk/NN
of/IN
fulminant/JJ
T1DM/NN
in/IN
Fisher/JJ
's/POS
exact/JJ
test/NN
(/(
odds/NNS
ratio/NN
[/(
OR/NN
]/)
,/,
4.11/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
[/(
CI/NN
]/)
,/,
1.56/CD
to/TO
10.86/CD
;/:
p/NN
=/JJ
0.009/CD
)/)
./.
====================
A/DT
histidine/NN
residue/NN
at/IN
HLA-DRβ1/NN
position/NN
13/CD
was/VBD
marginally/RB
associated/VBN
with/IN
increased/VBN
risk/NN
of/IN
fulminant/JJ
T1DM/NN
(/(
OR/NN
,/,
2.45/CD
;/:
95/CD
%/NN
CI/NN
,1.01/CD
to/TO
5.94/CD
;/:
p/NN
=/JJ
0.054/CD
)/)
./.
====================
Although/IN
we/PRP
had/VBD
limited/JJ
statistical/JJ
power/JJR
,/,
we/PRP
provide/VBP
evidence/NN
that/IN
HLA/NN
haplotype/NN
and/CC
amino/NN
acid/NN
change/NN
can/MD
be/VB
a/DT
genetic/JJ
risk/NN
factor/NN
of/IN
fulminant/JJ
T1DM/NN
in/IN
Koreans/NNS
./.
====================
Further/RB
large-scale/JJ
research/NN
is/VBZ
required/VBN
to/TO
confirm/VB
these/DT
findings/NNS
./.
====================
Fulminant/JJ
type/NN
1/CD
diabetes/VBZ
(/(
T1DM/NN
)/)
is/VBZ
a/DT
distinct/JJ
subtype/NN
of/IN
T1DM/NN
that/DT
is/VBZ
characterized/VBN
by/IN
rapid/JJ
onset/NN
of/IN
hyperglycemia/NN
and/CC
ketoacidosis/NN
with/IN
absolute/JJ
deficiency/NN
in/IN
insulin/NN
secretion/NN
,/,
and/CC
near/JJ
normal/JJ
glycated/JJ
hemoglobin/NN
(/(
HbA1c/NN
)/)
level/NN
at/IN
initial/JJ
presentation/NN
[/(
1/CD
]/)
./.
====================
It/PRP
was/VBD
first/JJ
described/VBN
in/IN
2000/CD
by/IN
Imagawa/NN
et/FW
al/JJ
./.
====================
[/(
2/CD
]/)
,/,
and/CC
was/VBD
defined/VBN
as/IN
diabetes/NNS
with/IN
remarkably/RB
rapid/JJ
onset/NN
(/(
within/IN
a/DT
few/JJ
days/NNS
)/)
and/CC
absolute/JJ
destruction/NN
of/IN
pancreatic/JJ
β-cells/NNS
./.
====================
The/DT
prevalence/NN
of/IN
fulminant/JJ
T1DM/NN
is/VBZ
not/RB
uncommon/JJ
and/CC
it/PRP
is/VBZ
estimated/VBN
to/TO
account/VB
for/IN
7.1/CD
%/NN
of/IN
all/DT
newly/RB
diagnosed/VBN
T1DM/NN
cases/NNS
in/IN
Korea/NN
[/(
3/CD
]/)
./.
====================
The/DT
detailed/JJ
pathogenesis/NN
of/IN
fulminant/JJ
T1DM/NN
is/VBZ
not/RB
fully/RB
understood/VBN
./.
====================
Both/DT
genetic/JJ
and/CC
environmental/JJ
factors/NNS
,/,
and/CC
their/PRP$
interaction/NN
contribute/VBP
to/TO
the/DT
development/NN
of/IN
fulminant/JJ
T1DM/NN
./.
====================
Regarding/VBG
genetic/JJ
factors/NNS
,/,
it/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
genotype/NN
and/CC
the/DT
HLADR4─HLA-DQ4/NN
haplotype/NN
play/VBP
a/DT
crucial/JJ
role/NN
in/IN
the/DT
predisposition/NN
to/TO
fulminant/JJ
T1DM/NN
./.
====================
Specifically/RB
,/,
the/DT
HLA-DRB1*04:05─HLA-DQB1*04:01/NN
haplotype/JJ
was/VBD
associated/VBN
with/IN
fulminant/JJ
T1DM/NN
by/IN
an/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
of/IN
2.9/CD
in/IN
Japanese/JJ
cases/NNS
(/(
n/NN
=/JJ
207/CD
)/)
and/CC
controls/VBZ
(/(
n/NN
=/JJ
325/CD
)/)
[/(
4/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
HLA-DRB1*09:01─HLA-DQB1*03:03/NN
haplotype/NN
was/VBD
also/RB
associated/VBN
with/IN
fulminant/JJ
T1DM/NN
by/IN
an/DT
OR/NN
of/IN
2.1/CD
[/(
4/CD
]/)
./.
====================
However/RB
,/,
these/DT
findings/NNS
have/VBP
not/RB
been/VBN
replicated/VBN
in/IN
other/JJ
populations/NNS
./.
====================
Recently/RB
,/,
three/CD
amino/NN
acid/NN
positions/NNS
(/(
HLA-DRβ1/NN
position/NN
13/CD
,/,
position/NN
71/CD
,/,
and/CC
HLA-DQβ1/NN
position/NN
57/CD
)/)
in/IN
the/DT
HLA-DR/NN
and/CC
HLA-DQ/NN
molecules/NNS
were/VBD
shown/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
T1DM/NN
in/IN
Europeans/NNS
[/(
5/CD
]/)
./.
====================
They/PRP
explained/VBN
90/CD
%/NN
of/IN
the/DT
phenotypic/JJ
variance/NN
in/IN
the/DT
HLA-DRB1─HLA-DQA1─HLA-DQB1/NN
locus/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
the/DT
HLA-DRB1─HLADQB1/NN
haplotype/JJ
and/CC
amino/NN
acid/NN
residues/NNS
at/IN
HLA-DRβ1/NN
position/NN
13/CD
and/CC
position/NN
71/CD
,/,
and/CC
HLA-DQβ1/NN
position/NN
57/CD
in/IN
11/CD
Korean/JJ
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
compared/VBD
their/PRP$
frequencies/NNS
with/IN
that/DT
of/IN
the/DT
Korean/JJ
Reference/NN
Panel/NN
obtained/VBN
from/IN
413/CD
participants/NNS
in/IN
the/DT
general/JJ
population/NN
[/(
6/CD
]/)
./.
====================
Study/NN
participants/NNS
====================
A/DT
total/JJ
of/IN
11/CD
cases/NNS
of/IN
fulminant/JJ
T1DM/NN
were/VBD
identified/VBN
at/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
between/IN
January/NN
2005/CD
and/CC
December/NN
2011/CD
and/CC
written/RB
informed/VBN
consent/NN
was/VBD
acquired/VBN
from/IN
the/DT
participants/NNS
./.
====================
The/DT
study/NN
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
(/(
IRB/NN
)/)
of/IN
the/DT
Clinical/JJ
Research/NN
Institute/JJ
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
(/(
IRB/NN
No/DT
./.
====================
0412-138-017/CD
and/CC
1205-130-411/CD
)/)
./.
====================
Peripheral/JJ
blood/NN
DNA/NN
was/VBD
used/VBN
for/IN
massive/JJ
parallel/NN
sequencing/NN
./.
====================
Whole/NN
exome/JJ
sequencing/NN
====================
Whole/IN
exome/DT
capture/NN
was/VBD
performed/VBN
with/IN
the/DT
SureSelect/NN
Human/JJ
All/DT
Exon/NN
Kit/NN
V4+UTRs/NNS
(/(
Agilent/JJ
Technologies/NNS
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
massive/JJ
parallel/NN
sequencing/NN
was/VBD
performed/VBN
with/IN
the/DT
HiSeq/JJ
2000/CD
Sequencing/NN
System/NN
(/(
Illumina/NN
Inc./NNP
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
sequence/NN
reads/VBZ
were/VBD
mapped/VBN
and/CC
aligned/VBD
to/TO
a/DT
human/JJ
reference/NN
genome/NN
using/VBG
Burrow-Wheeler/NN
Alignment/JJ
software/JJ
version/NN
0.7.12/CD
[/(
7/CD
]/)
./.
====================
The/DT
Genome/NN
Analysis/NN
Toolkit/NN
3.0/CD
HaplotypeCaller/NN
was/VBD
used/VBN
to/TO
identify/VB
single/JJ
nucleotide/NN
variations/NNS
,/,
insertions/NNS
,/,
and/CC
deletions/NNS
by/IN
multi-sample/JJ
calling/JJ
method/NN
[/(
8/CD
]/)
./.
====================
HLA/NN
imputation/NN
====================
For/IN
HLA/NN
genotype/NN
imputation/NN
,/,
SNP2HLA/NN
software/JJ
version/NN
1.0.3/CD
was/VBD
used/VBN
with/IN
default/NN
options/NNS
[/(
9/CD
]/)
./.
====================
Single/JJ
nucleotide/NN
variations/NNS
,/,
amino/NN
acid/NN
residues/NNS
,/,
and/CC
four-digit/VBD
classical/JJ
HLA/NN
alleles/NNS
of/IN
eight/CD
HLA/NN
genes/NNS
in/IN
chromosome/NN
6/CD
were/VBD
imputed/VBN
./.
====================
HLA/NN
haplotype/NN
was/VBD
inferred/VBN
with/IN
Beagle/JJ
version/NN
3.0.4/CD
[/(
10/CD
]/)
./.
====================
Imputation/NN
was/VBD
performed/VBN
based/VBN
on/IN
whole/JJ
exome/JJ
sequence/NN
genotype/NN
data/NNS
after/IN
quality/NN
control/NN
and/CC
as/IN
reference/RB
,/,
the/DT
pan-Asian/JJ
(/(
n/NN
=/JJ
530/CD
)/)
pre-built/VBP
reference/VBP
panel/NN
provided/VBD
by/IN
the/DT
SNP2HLA/NN
was/VBD
used/VBN
[/(
11/CD
]/)
./.
====================
An/DT
imputation/NN
quality/NN
score/RB
of/IN
r2/NN
>/JJR
0.3/CD
was/VBD
used/VBN
as/IN
the/DT
cut-off/JJ
./.
====================
Among/IN
the/DT
11/CD
fulminant/JJ
T1DM/NN
cases/NNS
,/,
we/PRP
validated/VBD
the/DT
HLA-DRB1/NN
and/CC
HLA-DQB1/NN
imputed/JJ
genotype/NN
in/IN
two/CD
participants/NNS
using/VBG
the/DT
AlleleSEQR/NN
HLA/NN
Sequencing/NN
Kit/NN
(/(
Atria/NN
Genetics/NNS
,/,
South/NN
San/JJ
Francisco/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
it/PRP
revealed/VBD
identical/JJ
results/NNS
./.
====================
For/IN
association/NN
testing/NN
we/PRP
used/VBD
the/DT
best-guessed/VBN
genotype/NN
in/IN
0/1/2/CD
format/IN
./.
====================
Statistical/JJ
analysis/NN
====================
As/IN
we/PRP
only/RB
had/VBD
genotype/JJ
data/NNS
from/IN
a/DT
small/JJ
number/NN
(/(
n/NN
=/JJ
11/CD
)/)
of/IN
fulminant/JJ
T1DM/NN
cases/NNS
,/,
we/PRP
tried/VBD
to/TO
describe/VB
the/DT
HLA/NN
genotype/NN
and/CC
haplotype/JJ
of/IN
each/DT
individual/JJ
,/,
as/IN
well/RB
as/IN
the/DT
recently/RB
reported/VBN
amino/NN
acid/NN
residues/NNS
at/IN
three/CD
major/JJ
positions/NNS
in/IN
the/DT
HLA-DR/NN
and/CC
HLA-DQ/NN
molecules/NNS
[/(
5/CD
]/)
./.
====================
For/IN
the/DT
case-control/JJ
analysis/NN
,/,
11/CD
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
413/CD
Korean/JJ
Reference/NN
Panel/NN
controls/NNS
were/VBD
compared/VBN
[/(
6/CD
]/)
./.
====================
Subject/JJ
having/VBG
two/CD
copies/NNS
of/IN
a/DT
specific/JJ
variant/JJ
was/VBD
classified/VBN
as/IN
Present/Present/JJ
,/,
having/VBG
only/RB
one/CD
copy/NN
was/VBD
defined/VBN
as/IN
Present/Absent/JJ
,/,
and/CC
having/VBG
none/NN
of/IN
the/DT
variants/NNS
was/VBD
considered/VBN
Absent/Absent/JJ
./.
====================
Fisher/RB
's/POS
exact/JJ
test/NN
was/VBD
performed/VBN
to/TO
compare/VB
the/DT
frequency/NN
of/IN
HLA/NN
haplotype/NN
or/CC
variant/JJ
in/IN
each/DT
locus/NN
and/CC
Cochran-Armitage/NN
trend/NN
test/NN
was/VBD
performed/VBN
to/TO
examine/VB
the/DT
linear/JJ
trend/NN
of/IN
three/CD
types/NNS
,/,
Present/Present/JJ
,/,
Present/Absent/JJ
,/,
and/CC
Absent/Absent/JJ
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
A/DT
p-value/JJ
of/IN
less/RBR
than/IN
0.05/CD
was/VBD
regarded/VBN
to/TO
be/VB
statistically/RB
significant/JJ
./.
====================
Assuming/VBG
a/DT
type/NN
1/CD
error/NN
rate/NN
of/IN
0.05/CD
and/CC
a/DT
variant/JJ
frequency/NN
of/IN
0.27/CD
in/IN
11/CD
cases/NNS
and/CC
0.08/CD
in/IN
413/CD
controls/NNS
,/,
our/PRP$
study/NN
had/VBD
a/DT
limited/JJ
statistical/JJ
power/JJR
of/IN
0.43/CD
using/VBG
Fisher/JJ
's/POS
exact/JJ
text/NN
./.
====================
Clinical/JJ
characteristics/NNS
====================
The/DT
clinical/JJ
characteristics/NNS
of/IN
the/DT
fulminant/JJ
T1DM/NN
cases/NNS
are/VBP
described/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
mean/JJ
age/NN
was/VBD
36.6/CD
±/CD
9.8/CD
y/RB
,/,
and/CC
mean/JJ
body/NN
mass/NN
index/NN
was/VBD
22.0/CD
±/CD
3.4/CD
kg/m2/NN
./.
====================
All/DT
participants/NNS
had/VBD
an/DT
HbA1c/NN
level/NN
of/IN
less/RBR
than/IN
7.0/CD
%/NN
except/IN
one/CD
patient/NN
who/WP
had/VBD
HbA1c/NN
of/IN
8.1/CD
%/NN
at/IN
initial/JJ
presentation/NN
of/IN
diabetic/JJ
ketoacidosis/NN
./.
====================
There/EX
was/VBD
absolute/JJ
deficiency/NN
in/IN
insulin/NN
secretion/NN
in/IN
all/DT
of/IN
the/DT
participants/NNS
and/CC
none/NN
of/IN
the/DT
participants/NNS
had/VBD
anti-glutamic/JJ
acid/NN
decarboxylase/NN
(/(
GAD/NN
)/)
autoantibody/NN
./.
====================
The/DT
HLA-DRB1─HLA-DQB1/NN
diplotype/JJ
of/IN
the/DT
four-digit/JJ
classical/JJ
allele/NN
of/IN
each/DT
individual/JJ
is/VBZ
described/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
amino/NN
acid/NN
residues/NNS
at/IN
HLA-DRβ1/NN
position/NN
13/CD
,/,
HLA-DRβ1/NN
position/NN
71/CD
,/,
and/CC
HLA-DQβ1/NN
position/NN
57/CD
are/VBP
also/RB
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
HLA-DRB1─HLA-DQB1/NN
haplotype/NN
analysis/NN
====================
The/DT
HLA-DRB1─HLA-DQB1/NN
haplotype/NN
frequencies/NNS
in/IN
11/CD
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
413/CD
Korean/JJ
Reference/NN
Panel/NN
subjects/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
2/CD
./.
====================
We/PRP
focused/VBD
on/IN
five/CD
haplotypes/NNS
that/WDT
were/VBD
reported/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
either/CC
increased/VBD
(/(
HLA-DRB1*04:05─HLA-DQB1*04:01/NN
,/,
HLA-DRB1*09:01─HLA-DQB1*03:03/NN
)/)
or/CC
decreased/VBD
(/(
HLA-DRB1*01:01─HLA-DQB1*05:01/NN
,/,
HLA-DRB1*15:02─HLADQB1*06:01/NN
,/,
and/CC
HLA-DRB1*08:03─HLA-DQB1*06:01/NN
)/)
risk/NN
of/IN
fulminant/JJ
T1DM/NN
in/IN
Japanese/JJ
./.
====================
We/PRP
found/VBD
that/IN
the/DT
frequency/NN
of/IN
the/DT
HLA-DRB1*04:05─HLA-DQB1*04:01/NN
haplotype/NN
was/VBD
0.27/CD
in/IN
Korean/JJ
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
0.08/CD
in/IN
the/DT
Korean/JJ
Reference/NN
Panel/NN
./.
====================
This/DT
haplotype/JJ
was/VBD
significantly/RB
associated/VBN
with/IN
a/DT
risk/NN
of/IN
fulminant/JJ
T1DM/NN
by/IN
Fisher/JJ
's/POS
exact/JJ
test/NN
(/(
OR/NN
,/,
4.11/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
[/(
CI/NN
]/)
,/,
1.56/CD
to/TO
10.86/CD
;/:
p=0.009/CD
)/)
./.
====================
None/NN
of/IN
the/DT
other/JJ
haplotypes/NNS
showed/VBD
a/DT
significant/JJ
association/NN
presumably/RB
due/JJ
to/TO
the/DT
limited/JJ
statistical/JJ
power/JJR
./.
====================
Three/CD
amino/NN
acid/NN
positions/NNS
in/IN
the/DT
HLA-DR/NN
and/CC
HLA-DQ/NN
molecules/NNS
====================
The/DT
frequency/NN
of/IN
amino/NN
acid/NN
residues/NNS
at/IN
HLA-DRβ1/NN
position/NN
13/CD
and/CC
position/NN
71/CD
,/,
and/CC
HLA-DQβ1/NN
position/NN
57/CD
and/CC
their/PRP$
association/NN
with/IN
fulminant/JJ
T1DM/NN
are/VBP
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
A/DT
histidine/NN
residue/NN
at/IN
HLA-DRβ1/NN
position/NN
13/CD
showed/VBD
marginal/JJ
association/NN
with/IN
fulminant/JJ
T1DM/NN
by/IN
Fisher/JJ
's/POS
exact/JJ
test/NN
(/(
OR/NN
,/,
2.45/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.01/CD
to/TO
5.94/CD
;/:
p/NN
=/JJ
0.054/CD
)/)
and/CC
Cochran-Armitage/NN
trend/NN
test/NN
(/(
p/NN
=/JJ
0.034/CD
)/)
./.
====================
However/RB
,/,
none/NN
of/IN
the/DT
other/JJ
amino/NN
acid/NN
residues/NNS
at/IN
the/DT
three/CD
positions/NNS
showed/VBD
a/DT
significant/JJ
association/NN
with/IN
fulminant/JJ
T1DM/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
investigated/VBN
the/DT
HLA/NN
genotype/NN
and/CC
haplotype/JJ
in/IN
11/CD
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
compared/VBD
its/PRP$
frequency/NN
with/IN
that/DT
of/IN
the/DT
general/JJ
population/NN
./.
====================
We/PRP
have/VBP
found/VBN
that/IN
the/DT
HLA-DRB1*04:05─HLA-DQB1*04:01/NN
haplotype/NN
is/VBZ
significantly/RB
associated/VBN
with/IN
increased/VBN
risk/NN
of/IN
fulminant/JJ
T1DM/NN
in/IN
Koreans/NNS
./.
====================
In/IN
addition/NN
,/,
a/DT
histidine/NN
residue/NN
at/IN
HLA-DRβ1/NN
position/NN
13/CD
showed/VBD
marginal/JJ
association/NN
with/IN
fulminant/JJ
T1DM/NN
./.
====================
To/TO
the/DT
best/JJS
of/IN
our/PRP$
knowledge/NN
,/,
this/DT
is/VBZ
the/DT
first/JJ
study/NN
to/TO
investigate/VB
the/DT
HLA-DR4─HLA-DQ4/NN
haplotype/NN
in/IN
fulminant/JJ
T1DM/NN
patients/NNS
from/IN
a/DT
population/NN
other/JJ
than/IN
Japanese/DT
./.
====================
We/PRP
also/RB
investigated/VBD
for/IN
the/DT
first/JJ
time/NN
the/DT
association/NN
between/IN
amino/NN
acid/NN
residues/NNS
in/IN
three/CD
positions/NNS
of/IN
the/DT
HLA-DR/NN
and/CC
HLA-DQ/NN
molecules/NNS
and/CC
the/DT
risk/NN
of/IN
fulminant/JJ
T1DM/NN
./.
====================
It/PRP
is/VBZ
well/RB
known/VBN
that/IN
HLA/NN
genes/NNS
account/VBP
for/IN
a/DT
significant/JJ
proportion/NN
of/IN
the/DT
susceptibility/NN
to/TO
T1DM/NN
[/(
12/CD
]/)
./.
====================
The/DT
complex/NN
genetic/JJ
structure/NN
of/IN
HLA/NN
loci/NNS
arising/VBG
from/IN
recombination/NN
,/,
gene/NN
conversion/NN
,/,
and/CC
natural/JJ
selection/NN
has/VBZ
been/VBN
a/DT
hurdle/JJ
in/IN
identifying/VBG
the/DT
precise/JJ
genetic/JJ
predisposition/NN
[/(
13/CD
]/)
./.
====================
However/RB
,/,
the/DT
linkage/NN
disequilibrium/NN
stretches/NNS
for/IN
a/DT
long-range/JJ
in/IN
the/DT
HLA/NN
loci/NNS
and/CC
it/PRP
is/VBZ
possible/JJ
to/TO
determine/VB
accurate/VBP
HLA/NN
genotype/NN
,/,
and/CC
haplotype/JJ
using/VBG
common/JJ
single/JJ
nucleotide/NN
variations/NNS
[/(
14/CD
]/)
./.
====================
The/DT
SNP2HLA/NN
software/JJ
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
a/DT
powerful/JJ
tool/NN
in/IN
imputing/VBG
HLA/NN
genotypes/NNS
in/IN
large-scale/JJ
genome-wide/NN
association/NN
studies/NNS
[/(
5/CD
]/)
./.
====================
However/RB
,/,
it/PRP
has/VBZ
not/RB
been/VBN
applied/VBN
to/TO
whole/JJ
exome/NN
sequence/NN
genotype/NN
data/NNS
./.
====================
We/PRP
have/VBP
applied/VBN
SNP2HLA/NN
in/IN
11/CD
cases/NNS
of/IN
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
successfully/RB
determined/VBN
HLA/NN
alleles/NNS
,/,
haplotypes/NNS
,/,
and/CC
amino/NN
acid/NN
residues/NNS
./.
====================
The/DT
classic/JJ
alleles/NNS
of/IN
HLA-DRB1/NN
and/CC
HLA-DQB1/NN
were/VBD
determined/VBN
by/IN
direct/JJ
genotyping/JJ
of/IN
two/CD
participants/NNS
of/IN
fulminant/JJ
T1DM/NN
and/CC
the/DT
results/NNS
were/VBD
consistent/JJ
with/IN
the/DT
imputed/JJ
genotypes/NNS
./.
====================
The/DT
most/JJS
well-known/JJ
HLA/NN
haplotype/NN
associated/VBN
with/IN
fulminant/JJ
T1DM/NN
is/VBZ
HLA-DRB1*04:05─HLA-DQB1*04:01/NN
./.
====================
In/IN
a/DT
large-scale/JJ
association/NN
analysis/NN
in/IN
Japanese/JJ
,/,
it/PRP
increased/VBD
the/DT
risk/NN
of/IN
fulminant/JJ
T1DM/NN
by/IN
2.9/CD
folds/VBZ
./.
====================
This/DT
haplotype/NN
was/VBD
also/RB
associated/VBN
with/IN
either/CC
acute/JJ
onset/NN
or/CC
slowly/RB
progressive/JJ
T1DM/NN
in/IN
Japanese/JJ
[/(
15/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
confirmed/VBD
this/DT
finding/NN
and/CC
the/DT
haplotype/NN
was/VBD
associated/VBN
with/IN
a/DT
4.11/CD
fold/JJ
increased/VBD
risk/NN
in/IN
Koreans/NNS
./.
====================
In/IN
the/DT
Korean/JJ
Reference/NN
Panel/NN
,/,
the/DT
HLA-DRB1*04:05/NN
allele/NN
and/CC
HLA-DQB1*04:01/NN
allele/NN
were/VBD
in/IN
perfect/JJ
linkage/NN
disequilibrium/NN
(/(
r2/NN
=/JJ
1.0/CD
)/)
./.
====================
Both/DT
the/DT
HLA-DRB1*04:05/NN
allele/NN
and/CC
HLA-DQB1*04:01/NN
allele/NN
were/VBD
also/RB
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
fulminant/JJ
T1DM/NN
(/(
p/NN
=/JJ
0.011/CD
by/IN
Fisher/NN
's/POS
exact/JJ
test/NN
)/)
./.
====================
Although/IN
there/EX
are/VBP
other/JJ
haplotypes/NNS
reported/VBD
to/TO
be/VB
associated/VBN
with/IN
fulminant/JJ
T1DM/NN
,/,
we/PRP
had/VBD
limited/JJ
statistical/JJ
power/JJR
to/TO
obtain/VB
a/DT
sound/JJ
conclusion/NN
./.
====================
In/IN
a/DT
recent/JJ
report/NN
investigating/VBG
the/DT
association/NN
of/IN
T1DM/NN
with/IN
amino/NN
acid/NN
residues/NNS
at/IN
three/CD
positions/NNS
of/IN
the/DT
HLA-DR/NN
and/CC
HLA-DQ/NN
molecules/NNS
,/,
HLA-DRβ1/NN
position/NN
13/CD
and/CC
position/NN
71/CD
,/,
and/CC
HLA-DQβ1/NN
position/NN
57/CD
explained/VBN
a/DT
significant/JJ
portion/NN
of/IN
phenotypic/JJ
variation/NN
conferred/VBD
by/IN
the/DT
HLA-DRB1─HLA-DQA1─HLA-DQB1/NN
locus/NN
./.
====================
We/PRP
have/VBP
identified/VBN
that/WDT
a/DT
histidine/NN
residue/NN
at/IN
HLA-DRβ1/NN
position/NN
13/CD
is/VBZ
marginally/RB
associated/VBN
with/IN
a/DT
2.45/CD
fold/JJ
increased/VBD
risk/NN
of/IN
fulminant/JJ
T1DM/NN
./.
====================
In/IN
Europeans/NNS
this/DT
residue/NN
was/VBD
associated/VBN
with/IN
a/DT
3.64/CD
fold/JJ
increased/VBD
risk/NN
of/IN
T1DM/NN
[/(
5/CD
]/)
./.
====================
This/DT
residue/NN
lines/NNS
the/DT
P4/NN
pocket/NN
of/IN
the/DT
HLA-DR/NN
molecule/NN
and/CC
was/VBD
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
rheumatoid/JJ
arthritis/NN
[/(
16/CD
]/)
./.
====================
It/PRP
could/MD
be/VB
speculated/VBN
that/DT
it/PRP
plays/VBZ
a/DT
role/NN
in/IN
the/DT
recognition/NN
of/IN
autoantigens/NNS
and/CC
autoimmunity/NN
[/(
5/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
difficult/JJ
to/TO
have/VB
a/DT
direct/JJ
comparison/NN
of/IN
our/PRP$
results/NNS
with/IN
that/DT
of/IN
T1DM/NN
in/IN
Europeans/NNS
,/,
and/CC
it/PRP
is/VBZ
not/RB
known/VBN
whether/IN
these/DT
amino/NN
acid/NN
residues/NNS
in/IN
the/DT
three/CD
positions/NNS
are/VBP
also/RB
major/JJ
risk/NN
determinants/NNS
of/IN
T1DM/NN
in/IN
East/JJ
Asians/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
similarities/NNS
in/IN
genetic/JJ
predisposition/NN
between/IN
fulminant/JJ
T1DM/NN
and/CC
other/JJ
types/NNS
of/IN
T1DM/NN
require/VBP
further/RBR
investigation/NN
./.
====================
It/PRP
has/VBZ
been/VBN
suggested/VBN
that/IN
the/DT
genetic/JJ
predisposition/NN
predisposition/NN
conferred/VBD
by/IN
the/DT
HLA/NN
locus/NN
could/MD
be/VB
different/JJ
between/IN
fulminant/JJ
T1DM/NN
and/CC
other/JJ
types/NNS
of/IN
T1DM/NN
in/IN
Japanese/JJ
[/(
15/CD
]/)
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
have/VBP
investigated/VBN
the/DT
HLA/NN
genotype/NN
and/CC
haplotype/JJ
in/IN
11/CD
Korean/JJ
fulminant/JJ
T1DM/NN
cases/NNS
and/CC
provide/VBP
evidence/NN
that/IN
HLA-DRB1*04:05─HLA-DQB1*04:01/NN
is/VBZ
an/DT
important/JJ
genetic/JJ
risk/NN
factor/NN
of/IN
fulminant/JJ
T1DM/NN
./.
====================
There/EX
is/VBZ
suggestive/JJ
evidence/NN
that/IN
a/DT
histidine/NN
residue/NN
at/IN
HLA-DRβ1/NN
position/NN
13/CD
which/WDT
lines/NNS
the/DT
P4/NN
pocket/NN
of/IN
the/DT
HLA-DR/NN
molecule/NN
,/,
might/MD
increase/VB
the/DT
risk/NN
of/IN
fulminant/JJ
T1DM/NN
in/IN
Koreans/NNS
./.
====================
Further/RB
large-scale/JJ
investigation/NN
is/VBZ
required/VBN
to/TO
confirm/VB
our/PRP$
findings/NNS
./.
====================
Clinical/JJ
characteristics/NNS
and/CC
HLA/NN
diplotypes/NNS
of/IN
study/NN
participants/NNS
====================
Haplotype/NN
frequency/NN
and/CC
association/NN
with/IN
fulminant/JJ
T1DM/NN
====================
Three/CD
amino/NN
acid/NN
positions/NNS
at/IN
HLA-DR/NN
and/CC
HLA-DQ/NN
and/CC
association/NN
with/IN
fulminant/JJ
T1DM/NN
====================
